Fig 1: Effects of THSG on Sesn2, AMPK and mTOR levels in UB/OC-2 cochlear cells following gentamicin treatment. (A) UB/OC-2 cochlear cells were pretreated with 5, 10 and 20 µM THSG for 6 h and then cotreated with 750 µM gentamicin for 16 h. The expression levels of Sesn2 mRNA were evaluated using reverse-transcription-quantitative PCR. GAPDH was used as an internal control. n=3 per group. UB/OC-2 cochlear cells were pretreated with 5, 10 and 20 µM THSG for 6 h and then cotreated with 750 µM gentamicin for 24 h. Protein expression of Sesn2 (B), p-AMPK and AMPK (C), p-mTOR and mTOR (D) were evaluated by western blotting. ß-actin was used as a loading control. n=3 per group. Quantitative data are expressed as mean ± SD. **P<0.01 compared with the control group; #P<0.05, ##P<0.01 vs. the gentamicin group. THSG, 2,3,4',5-tetrahydroxystilbene-2-O-ß-D-glucoside; AMPK, AMP-activated protein kinase; p-, phosphorylated.